All In Biotech

Drug Trial Radar · NCT04516057

Nabilone for Agitation Blinded Intervention Trial

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Feb 1, 2021

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alzheimer's Drug Discovery Foundation
First posted
Aug 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events. Therefore, identifying safer and more effective treatments for agitation in AD is a clinical and research priority. Nabilone is a synthetic cannabinoid that is Health Canada-approved to treat chemotherapy-induced nausea and vomiting. The PI's research group completed a 6-week double-blind placebo-controlled randomized cross-over pilot trial in 38 patients with moderate-to-severe AD, providing the first preliminary evidence regarding the safety and efficacy of nabilone in this population. They found that nabilone significantly improved agitation, overall neuropsychiatric symptoms, and caregiver distress. That study was limited by its sample size and questions remain regarding the efficacy of nabilone for nutrition and pain and predictors of response. However, the promising preliminary findings encourage a pivotal, practice-changing phase III trial to inform clinical practice. Participants in this study will be randomized to receive either nabilone or a placebo for 8 weeks. In addition to looking at the effectiveness of nabilone in treating agitation, the researchers will also look at whether it is beneficial for other relevant outcomes for patients with AD including overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, and pain. Participants will also be followed for 8 weeks following completion of the study treatment.

Conditions

  • Alzheimer Disease
  • Agitation

Interventions

  • NabiloneDrug

    After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

  • PlaceboOther

    After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Agitation - Cohen-Mansfield Agitation Inventory (CMAI)Time frame: Baseline (0 Weeks) to 8 Weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Geras Centre for Aging Research, Hamilton Health Sciences

    Hamilton, Ontario, Canada · Not yet recruiting

  • London Health Sciences Centre

    London, Ontario, Canada · Recruiting

  • The University of Ottawa Institute of Mental Health Research at The Royal

    Ottawa, Ontario, Canada · Not yet recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada · Recruiting

  • St. Michael's Hospital

    Toronto, Ontario, Canada · Terminated

  • Ontario Shores Centre for Mental Health Sciences

    Whitby, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.